Generic Name and Formulations:
Lorazepam 0.5mg, 1mg+, 2mg+; tabs; +scored.
Bausch Health Companies Inc.
Indications for ATIVAN:
Give in 2 or 3 divided doses, with largest dose taken at bedtime. Individualize. Initially 2–3mg daily; range: 1–10mg daily. Elderly or debilitated: initially 1–2mg daily; adjust gradually if needed.
Acute narrow-angle glaucoma.
Risks from concomitant use with opioids; see Interactions. Therapy for >4 months. Discontinue if paradoxical reactions occur. Primary depressive disorder or psychosis: not recommended. Suicidal tendencies (monitor). Renal or hepatic impairment. Compromised respiratory function. Seizure disorder. Reevaluate periodically. Monitor blood counts, liver function with long-term use. Abuse potential (monitor). Drug or alcohol abuse. Avoid abrupt cessation. Change dose gradually. Elderly. Debilitated. Pregnancy (during the 1st trimester), nursing mothers: not recommended.
Increased sedation, respiratory depression, coma, and death with concomitant opioids; reserve use in those for whom alternative treatment options are inadequate; if needed, limit dosages/durations to minimum and monitor. Potentiation of CNS depression with alcohol, other CNS depressants (eg, barbiturates, antipsychotics, sedatives/hypnotics, anxiolytics, others). Caution with clozapine. May be potentiated by probenecid or valproate (reduce lorazepam dose by 50%). May be antagonized by theophylline, aminophylline.
CNS depression (esp. sedation), dizziness, weakness, unsteadiness, transient memory impairment, confusion, disorientation, nausea, change in appetite, headache, sleep apnea.
Tabs—100, 500, 1000
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Examining the Efficacy of Different Oxygen Flow Rates for Cluster Headache Attacks
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds